Tags

Type your tag names separated by a space and hit enter

Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2) Antibody Responses in Children With Multisystem Inflammatory Syndrome in Children (MIS-C) and Mild and Severe Coronavirus Disease 2019 (COVID-19).
J Pediatric Infect Dis Soc. 2021 May 28; 10(5):669-673.JP

Abstract

Severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) antibody responses in children remain poorly characterized. Here, we show that pediatric patients with multisystem inflammatory syndrome in children (MIS-C) possess higher SARS-CoV-2 spike immunoglobulin G (IgG) titers compared with those with severe coronavirus disease 2019, likely reflecting a longer time since the onset of infection in MIS-C patients.

Authors+Show Affiliations

Department of Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.Immune Dysregulation Frontier Program, Department of Pediatrics, Children's Hospital of Philadelphia, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA. Department of Pediatrics, Division of Oncology, Children's Hospital of Philadelphia, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.Department of Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.Immune Dysregulation Frontier Program, Department of Pediatrics, Children's Hospital of Philadelphia, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA. Department of Pediatrics, Division of Oncology, Children's Hospital of Philadelphia, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.Department of Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.Department of Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.Department of Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.Department of Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.Immune Dysregulation Frontier Program, Department of Pediatrics, Children's Hospital of Philadelphia, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA. Department of Pediatrics, Division of Rheumatology, Children's Hospital of Philadelphia, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.Department of Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA. School of Veterinary Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.Department of Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.Institute for Immunology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA. Department of Systems Pharmacology and Translational Therapeutics, University of Pennsylvania, Philadelphia, Pennsylvania, USA.Institute for Immunology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA. Department of Systems Pharmacology and Translational Therapeutics, University of Pennsylvania, Philadelphia, Pennsylvania, USA.Immune Dysregulation Frontier Program, Department of Pediatrics, Children's Hospital of Philadelphia, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.Immune Dysregulation Frontier Program, Department of Pediatrics, Children's Hospital of Philadelphia, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.Institute for Immunology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA. Department of Systems Pharmacology and Translational Therapeutics, University of Pennsylvania, Philadelphia, Pennsylvania, USA. Department of Pediatrics, Division of Infectious Diseases, Children's Hospital of Philadelphia, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.Department of Pediatrics, Division of Allergy and Immunology, Children's Hospital of Philadelphia, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.Department of Pathology and Laboratory Medicine, Children's Hospital of Philadelphia, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.Institute for Immunology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA. Department of Systems Pharmacology and Translational Therapeutics, University of Pennsylvania, Philadelphia, Pennsylvania, USA.Department of Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA. Penn Center for Research on Coronavirus and Other Emerging Pathogens, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.Immune Dysregulation Frontier Program, Department of Pediatrics, Children's Hospital of Philadelphia, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA. Department of Pediatrics, Division of Infectious Diseases, Children's Hospital of Philadelphia, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.Immune Dysregulation Frontier Program, Department of Pediatrics, Children's Hospital of Philadelphia, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA. Department of Pediatrics, Division of Rheumatology, Children's Hospital of Philadelphia, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.Immune Dysregulation Frontier Program, Department of Pediatrics, Children's Hospital of Philadelphia, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA. Department of Pediatrics, Division of Oncology, Children's Hospital of Philadelphia, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.Department of Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

33263756

Citation

Anderson, Elizabeth M., et al. "Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2) Antibody Responses in Children With Multisystem Inflammatory Syndrome in Children (MIS-C) and Mild and Severe Coronavirus Disease 2019 (COVID-19)." Journal of the Pediatric Infectious Diseases Society, vol. 10, no. 5, 2021, pp. 669-673.
Anderson EM, Diorio C, Goodwin EC, et al. Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2) Antibody Responses in Children With Multisystem Inflammatory Syndrome in Children (MIS-C) and Mild and Severe Coronavirus Disease 2019 (COVID-19). J Pediatric Infect Dis Soc. 2021;10(5):669-673.
Anderson, E. M., Diorio, C., Goodwin, E. C., McNerney, K. O., Weirick, M. E., Gouma, S., Bolton, M. J., Arevalo, C. P., Chase, J., Hicks, P., Manzoni, T. B., Baxter, A. E., Andrea, K. P., Burudpakdee, C., Lee, J. H., Vella, L. A., Henrickson, S. E., Harris, R. M., Wherry, E. J., ... Hensley, S. E. (2021). Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2) Antibody Responses in Children With Multisystem Inflammatory Syndrome in Children (MIS-C) and Mild and Severe Coronavirus Disease 2019 (COVID-19). Journal of the Pediatric Infectious Diseases Society, 10(5), 669-673. https://doi.org/10.1093/jpids/piaa161
Anderson EM, et al. Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2) Antibody Responses in Children With Multisystem Inflammatory Syndrome in Children (MIS-C) and Mild and Severe Coronavirus Disease 2019 (COVID-19). J Pediatric Infect Dis Soc. 2021 May 28;10(5):669-673. PubMed PMID: 33263756.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2) Antibody Responses in Children With Multisystem Inflammatory Syndrome in Children (MIS-C) and Mild and Severe Coronavirus Disease 2019 (COVID-19). AU - Anderson,Elizabeth M, AU - Diorio,Caroline, AU - Goodwin,Eileen C, AU - McNerney,Kevin O, AU - Weirick,Madison E, AU - Gouma,Sigrid, AU - Bolton,Marcus J, AU - Arevalo,Claudia P, AU - Chase,Julie, AU - Hicks,Philip, AU - Manzoni,Tomaz B, AU - Baxter,Amy E, AU - Andrea,Kurt P, AU - Burudpakdee,Chakkapong, AU - Lee,Jessica H, AU - Vella,Laura A, AU - Henrickson,Sarah E, AU - Harris,Rebecca M, AU - Wherry,E John, AU - Bates,Paul, AU - Bassiri,Hamid, AU - Behrens,Edward M, AU - Teachey,David T, AU - Hensley,Scott E, PY - 2020/09/15/received PY - 2020/12/01/accepted PY - 2020/12/3/pubmed PY - 2021/6/4/medline PY - 2020/12/2/entrez KW - COVID-19 KW - SARS-COV-2 KW - antibodies KW - multisystem inflammatory syndrome in children (MIS-C) KW - pediatric SP - 669 EP - 673 JF - Journal of the Pediatric Infectious Diseases Society JO - J Pediatric Infect Dis Soc VL - 10 IS - 5 N2 - Severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) antibody responses in children remain poorly characterized. Here, we show that pediatric patients with multisystem inflammatory syndrome in children (MIS-C) possess higher SARS-CoV-2 spike immunoglobulin G (IgG) titers compared with those with severe coronavirus disease 2019, likely reflecting a longer time since the onset of infection in MIS-C patients. SN - 2048-7207 UR - https://www.unboundmedicine.com/medline/citation/33263756/Severe_Acute_Respiratory_Syndrome_Coronavirus_2__SARS_CoV_2__Antibody_Responses_in_Children_With_Multisystem_Inflammatory_Syndrome_in_Children__MIS_C__and_Mild_and_Severe_Coronavirus_Disease_2019__COVID_19__ L2 - https://academic.oup.com/jpids/article-lookup/doi/10.1093/jpids/piaa161 DB - PRIME DP - Unbound Medicine ER -